M2 EQUITYBITES-October 19, 2016-Actinium Pharmaceuticals wins EMA orphan designation for radioimmunoconjugate
M2 PHARMA-October 19, 2016-Actinium Pharmaceuticals wins EMA orphan designation for radioimmunoconjugate
Rituximab is given to enable clearance of peripheral B-cells and to maximize biodistribution prior to radioimmunoconjugate
Another novel yet effective treatment is radio immunotherapy (RIT) which allows delivery of radiation to lymphoma cells using radioimmunoconjugates
(I- tositumomab and Y-ibritutomomab tiuxetan have been approved till now) that target the CD20 antigen and are being used in the setting of recurrent follicular lymphoma setting.
Yttrium90, Iodine131, ibritumomab tiuxetan are the currently used radioimmunoconjugates
Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates
Future immunotherapy-based treatments will be enhanced by the radioimmunoconjugates
and vaccine therapy.